China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in combination with Janssen’s Rekambys (rilpivirine long-acting injection) for the treatment of human immunodeficiency virus type-1 (HIV-1) infection.
Vocabria is indicated in combination with Rekambys for the treatment of HIV-1 in adult patients who are virologically suppressed and on a stable antiretroviral (ARV) regiment without present or past evidence of viral resistance to, and no prior virological failure with, agents of the non-nucleoside reverse transcriptase inhibitor (NNRTI) and integrase inhibitor (INI) classes.
The drug is approved in tablet form for use alongside Edurant (rilpivirine tablets) as an optional oral lead-in before beginning dosing with the injections or for use as an oral therapy for patients who may miss planned injection doses.
Deborah Waterhouse, CEO of ViiV Healthcare, commented: “At ViiV Healthcare, we are proud to be able to offer innovative solutions that meet the evolving needs of people living with HIV. The approval of cabotegravir injection and rilpivirine long-acting injection marks a step forward in helping to change the treatment experience for some people living with HIV in China who may have challenges with daily HIV therapies. We look forward to working closely with our partners in China to make this treatment available to those who could benefit from a long-acting regimen, part of our commitment to ensuring no person living with HIV is left behind.”
CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved …
GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines …